Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. - Wikidata - wikimedia - TriplyDB

Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.

Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.

http://www.wikidata.org/entity/Q37956603

about

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis The Role of MicroRNAs in Myeloproliferative Neoplasia Guidelines for the management of myeloproliferative neoplasms The evolving treatment paradigm in myelofibrosis Association of Oesophageal Varices and Splanchnic Vein Thromboses in Patients with JAK2-Positive Myeloproliferative Neoplasms: Presentation of Two Cases and Data from a Retrospective Analysis.Ruxolitinib: a new treatment option for myelofibrosis.Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.Ruxolitinib for myelofibrosis--an update of its clinical effects.Identification of submicroscopic genetic changes and precise breakpoint mapping in myelofibrosis using high resolution mate-pair sequencing.Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.Ruxolitinib Associated Tuberculosis Presenting as a Neck Lump.An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.Xist RNA is a potent suppressor of hematologic cancer in mice.Treatment and management of myelofibrosis in the era of JAK inhibitors WHO classification of myeloproliferative neoplasms (MPN): A critical update.MPL W515L expression induces TGFβ secretion and leads to an increase in chemokinesis via phosphorylation of THOC5.Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis.Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis.Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.

P2860

Q24186554-EB478842-B19F-43FE-B9E2-DE7C84A979AD Q24201893-AEFBAE9D-5947-42FF-B01C-2339DA3A5C98 Q26739435-10C050FB-75C7-429C-8878-96A1B8F5734D Q26778326-3218994D-6DF4-4856-9134-692624185431 Q27021968-A4D8B76C-9F45-4003-978F-8BD7F0E0FF8F Q30658101-E64347CE-F265-4DD8-ADBB-60EC063FF6A7 Q33405241-D4B08320-7DA0-4B31-802B-D7D1BB053D97 Q33407924-D5F7AC99-6AE5-4123-ABDA-E3A92DBCF71C Q33411502-35B58AD8-A9B4-4D1D-89AB-E1692294F560 Q34348505-C75C0195-3153-4781-B6EA-19AD4073FC8F Q34434935-1BF8EB1C-E25A-4BAC-87CA-2B34DC335760 Q36409003-BEF53575-D6B4-4D3C-BD71-96DFEA5F9B6F Q36708989-AA50381E-0B75-4219-AB84-DCC5F55F9980 Q36776428-526D9C9B-A662-4B94-8F4F-E9A0E00CE3EE Q37419610-DFA15E87-8E5B-4334-AA5F-4DF168343F7F Q38132739-C56948AF-E907-485D-959A-BFB279E34DF1 Q38154519-B0935B90-F885-4413-A9E4-088B601FFD33 Q41787058-72392555-EF59-4575-A744-83C070F77294 Q44678769-B94FD735-C234-4A0F-BFE2-47600FE104E0 Q52640385-C011D6DE-05FA-4C5E-B611-C100FDDDC6C4 Q54250506-DFB2204C-F5E2-46BD-B131-25CF1BF66235 Q54518446-75EBC85F-BE8A-4E82-AC18-FFE8CB76DA6C

P2860

Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.

http://www.wikidata.org/entity/Q37956603

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.

@en

Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.

@nl

type

label

Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.

@en

Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.

@nl

prefLabel

Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.

@en

Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.

@nl

P1433

Q37956603-3E631083-5349-4352-8EB7-11BA276D522A

P1476

Q37956603-05DD33F2-DC2C-467C-80F2-776C8759B224

P2860

Q37956603-0AF2D2B3-75D7-426E-9922-BF5D08E6ABDB

Q37956603-10C250A6-43E5-4ADA-B49A-B8E7C59DF37F

Q37956603-173CD085-3D4D-4566-92DE-86A7AB13580B

Q37956603-1C5BDCBC-995F-46BC-82B7-9BA908C245A7

Q37956603-2A89A741-D13F-4005-8898-722F27CE51E7

Q37956603-2C005606-E799-410B-A547-21F1D3995019

Q37956603-317134CD-A881-4E08-A8A9-263E6297A76A

Q37956603-326C9831-43EC-447C-BED9-8B143EB3DEBC

Q37956603-3C3B955A-8901-4C14-A151-D04ECC34D34C

Q37956603-40404D5A-B029-4958-AB80-9337601FDE1B

P304

Q37956603-C144836A-EDE4-41C7-9442-4F69815D69C3

P31

Q37956603-D76A619E-E68A-4B28-9225-E981AB6F1A38

P356

Q37956603-68F0B59D-D3FA-4CEA-B6A3-9E1B32735A10

P433

Q37956603-FA2696CA-D124-4C6D-85CA-6EC48A6329BD

P478

Q37956603-983934E1-8B7F-498C-92E7-3131F8DFDCEC

P50

Q37956603-3181881D-5177-4721-B974-F2916396616F

P577

Q37956603-3D660F3B-73ED-40AB-841E-E6E86ED89EC9

P5875

Q37956603-2BB3CC11-FF26-4C85-801B-60026C43396D

P698

Q37956603-A643AABA-9F66-42AD-BF6A-1AB83FDA1074

P921

Q37956603-9cd946c4-8078-4434-a998-130282d2c1f8

P356

P1433

American Journal of Hematology

P1476

Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.

@en

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.

New and old treatment modalities in primary myelofibrosis.

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

P304

1017-1026

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.22210

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51802056

http://www.w3.org/2001/XMLSchema#string

P698

22086865

http://www.w3.org/2001/XMLSchema#string

P921